Skip to main content
All lobbying filings

PHLOW CORPORATION

PHLOW CORPORATION filed a Q4 report for PHLOW CORPORATION on January 20, 2026.

Lobbying for PHLOW CORPORATION

All filings by PHLOW CORPORATION · Everything PHLOW CORPORATION has reported

 Filing · LD-2 quarterly report Q4 report
Reporting period
4th Quarter 2025
Oct 1 - Dec 31 · Posted Jan 20, 2026
Expenses
$410,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Virginia

Official filing document

 Government bodies contacted 7

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 3
Budget/Appropriations

FY26 Labor, Health and Human Services, Education, and Related Agencies Appropriations (H.R. 5304/S.2587); FY26 Department of Defense Appropriations (H.R. 4016/S.2572/S.2296/S.4638)

Health Issues

Administrations activities related to supply chain and domestic capacity; Department of Defense activities related to pharmaceutical and medical countermeasure supply chain for the warfighter; S.1784, Mapping America's Pharmaceutical Supply (MAPS) Act, provisions related to the improvement of coordination of Federal efforts to identify and mitigate health and national security risks; S.2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, provisions related to improving supply chain resiliency for critical drug products with vulnerable supply chains; H.R.3966, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act. (identical legislation)

Manufacturing

Administrations activities related to supply chain and domestic capacity; Department of Defense activities related to pharmaceutical and medical countermeasure supply chain for the warfighter; S.1784, Mapping America's Pharmaceutical Supply (MAPS) Act, provisions related to the improvement of coordination of Federal efforts to identify and mitigate health and national security risks; S.2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, provisions related to improving supply chain resiliency for critical drug products with vulnerable supply chains; H.R.3966, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act. (identical legislation)

 Bills named in this filing 9
  • H.R. 5304
    Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
  • S. 2587
    Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
  • H.R. 4016
    Department of Defense Appropriations Act, 2026
  • S. 2572
    Department of Defense Appropriations Act, 2026
  • S. 2296
    National Defense Authorization Act for Fiscal Year 2026
  • S. 4638
    National Defense Authorization Act for Fiscal Year 2025
  • S. 1784
    MAPS Act
  • S. 2062
    RAPID Reserve Act
  • H.R. 3966
    Improving Atmospheric River Forecasts Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem